



RUTGERS

iJOBS Seminar: Startups and Fellowship Opportunities

Tuesday, September 20, 2022

12:00 PM



Jason Huang

Director of Program Management

Delphine Diagnostics

jason.huang@delphinedx.com

Jason Huang is the Director of Program Management at Delphine Diagnostics. He was most recently a consultant for biopharma companies. Prior to that Jason served as director of continuous process improvement (CPI) at Johnson & Johnson (JNJ) between 2014 and 2018. He led a team executing projects/programs across the worldwide enterprise in all three sectors — pharmaceutical, medical devices, and consumer healthcare products. Before joining JNJ, Jason served as director of continuous improvement (CI) for a 350-person strategic business unit of Automatic Data Processing (ADP) LLC between 2013 and 2014. From 2003 to 2013, Jason held a series of roles, including project manager, software development leader, and information technology program manager for corporate functions at Honeywell International Inc. Jason earned a bachelor's degree in biological sciences at Cornell University and a master's degree in technology management at Stevens Institute of Technology.

Founded in June 2020, Delphine Diagnostics develops and markets clinical diagnostics products in the diagnosis of underlying pathogens leading to infectious disease and life-threatening conditions, such as sepsis and septic shock. Our RT-PCR Diagnostic Kit for SARS-CoV-2 (the virus attributed to COVID-19) is undergoing regulatory review under the Emergency Use Authorization (EUA) pathway. We are developing (in collaboration with Raja Duraisamy) an artificial intelligence-enabled, results-interpretation engine. This clinical decision accelerator will combine the raw data from clinical diagnostics and that of an electronic medical record/health record system, such as Epic, to produce a suggestion called Recommended Next Action. In turn, we aim to reduce the time it takes for a clinician to arrive at the very best next action for a given patient in sepsis or at risk of developing sepsis.



Viraj Mane, PhD

Co-founder and Chief Scientific Officer

Lactiga

viraj@lactiga.com

www.lactiga.com

Lactiga is an award-winning, venture-backed Biotherapeutics and Med Device company developing novel biologics to treat and prevent infections including COVID-19, with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk to create the next generation of anti-infectives that can battle even the world's most dangerous

pathogens. Viraj has a PhD from Baylor in Molecular and Human Genetics and attended The College of NJ for his Bachelors.



Roelof Rongen

CEO and Founder

Innovative Molecules

roelof@innovative-molecules.com

Roelof Rongen is the CEO and Founder of Innovative Molecules, a small drug development company focused on self-funded development and business-partner-programs. He is a serial entrepreneur and R&D / Commercial Development leader with extensive experience across many therapeutic areas and functions. Roelof founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB), he was a member of the founding team of Reliant Pharmaceutical (now GSK), and was integral to the development and commercialization of blockbuster brands such as Humira® and Lovaza®. Roelof has a degree in Molecular Sciences and an MBA.